| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60970748dd11974288b480f8fb0af862
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffcc8198e479e0e4a9dccb132e679913
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e64179a6fe64333e00e51a455eabdf45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-103
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-083 |
| filingDate |
2002-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16ac1555f6c2c44823c17da23498269d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b905a0a97ecaaf10cfd119ca8c12050 |
| publicationDate |
2002-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02083729-A2 |
| titleOfInvention |
Polypeptides derived from amyloid precursor peptide (app) and their uses |
| abstract |
The invention provides a compound having formula X1-Arg-Xaa-Arg-X2 in which X1 and X2 are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compound is the tripeptide Arg-Glu-Arg which corresponds to amino acid residues 328 to 330 of human amyloid precursor protein. The invention further provides a derivative of a polypeptide having the formula: X1-Arg-Xaa-Arg-X2 wherein X1 and X2, which may be the same or different, each represents from zero to 30 natural or synthetic amino acid residues or derivatives thereof and Xaa represents a natural or synthetic amino acid residue or derivative thereof, at least one functional group of at least one said amino acid residue or derivative thereof being protected by a protective group. The compounds of the invention are believed to be useful in the treatment of Alzheimer's disease and as cognitive enhancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007060486-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2228388-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2432586-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009517376-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9655848-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007060486-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015283078-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2432586-A |
| priorityDate |
2001-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |